[A trial of treatment with thymus factor (TFX) for chronic autoimmune hemolytic anemias]

30 days treatment TFX was performed in 8 cases AIHA (autoimmune hemolytic anemia) with presence of warm antibodies refractory after routine treatment (glucocorticosteroids, azathioprine, splenectomy): After TFX treatment in 2 cases autoantibodies were not detectable, in 5 cases reaction DAT (direct antiglobulin test) was decreased. Eluate antibody level and serum antibody level were decreased, too. Decreasing amount of red cells autoantibodies was confirmed by enzyme-linked antiglobulin test (ELAT) in 2 cases. Autoantibody level measured by semiquantitative and quantitative methods did not increase in any other case. Adverse effects of TFX treatment were not observed.